As of 2026-03-21, the EV/EBITDA ratio of ACADIA Pharmaceuticals Inc (ACAD) is -23.73. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Acadia's latest enterprise value is 2,716.28 mil USD. Acadia's TTM EBITDA according to its financial statements is -114.49 mil USD. Dividing these 2 quantities gives us the above Acadia EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 7.9x - 10.1x | 8.6x |
| Forward P/E multiples | 7.8x - 12.7x | 9.4x |
| Fair Price | (0.50) - 16.19 | 6.10 |
| Upside | -102.4% - -22.0% | -70.6% |
| Date | EV/EBITDA |
| 2026-03-18 | -23.00 |
| 2026-03-17 | -23.96 |
| 2026-03-16 | -24.69 |
| 2026-03-13 | -23.53 |
| 2026-03-12 | -24.52 |
| 2026-03-11 | -25.56 |
| 2026-03-10 | -26.41 |
| 2026-03-09 | -26.47 |
| 2026-03-06 | -25.84 |
| 2026-03-05 | -26.20 |
| 2026-03-04 | -27.67 |
| 2026-03-03 | -26.35 |
| 2026-03-02 | -26.81 |
| 2026-02-27 | -29.41 |
| 2026-02-26 | -29.53 |
| 2026-02-25 | -30.03 |
| 2026-02-24 | -29.46 |
| 2026-02-23 | -29.67 |
| 2026-02-20 | -28.57 |
| 2026-02-19 | -29.07 |
| 2026-02-18 | -27.39 |
| 2026-02-17 | -27.02 |
| 2026-02-13 | -25.65 |
| 2026-02-12 | -25.02 |
| 2026-02-11 | -26.30 |
| 2026-02-10 | -26.64 |
| 2026-02-09 | -27.42 |
| 2026-02-06 | -27.93 |
| 2026-02-05 | -27.78 |
| 2026-02-04 | -28.92 |
| 2026-02-03 | -29.71 |
| 2026-02-02 | -31.75 |
| 2026-01-30 | -30.26 |
| 2026-01-29 | -31.11 |
| 2026-01-28 | -30.99 |
| 2026-01-27 | -31.86 |
| 2026-01-26 | -32.84 |
| 2026-01-23 | -32.81 |
| 2026-01-22 | -33.81 |
| 2026-01-21 | -32.69 |
| 2026-01-20 | -31.99 |
| 2026-01-16 | -31.54 |
| 2026-01-15 | -32.35 |
| 2026-01-14 | -32.84 |
| 2026-01-13 | -32.24 |
| 2026-01-12 | -32.44 |
| 2026-01-09 | -32.72 |
| 2026-01-08 | -32.91 |
| 2026-01-07 | -33.67 |
| 2026-01-06 | -32.96 |